Literature DB >> 9104804

Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.

D Martin1, N Cadieux, J Hamel, B R Brodeur.   

Abstract

A new surface protein, named NspA, which is distinct from the previously described Neisseria meningitidis outer membrane proteins was identified. An NspA-specific mAb, named Me-1, reacted with 99% of the meningococcal strains tested indicating that the epitope recognized by this particular mAb is widely distributed and highly conserved. Western immunoblotting experiments indicated that mAb Me-1 is directed against a protein band with an approximate molecular mass of 22,000, but also recognized a minor protein band with an approximate molecular mass of 18,000. This mAb exhibited bactericidal activity against four meningococcal strains, two isolates of serogroup B, and one isolate from each serogroup A and C, and passively protected mice against an experimental infection. To further characterize the NspA protein and to evaluate the protective potential of recombinant NspA protein, the nspA gene was identified and cloned into a low copy expression vector. Nucleotide sequencing of the meningococcal insert revealed an ORF of 525 nucleotides coding for a polypeptide of 174 amino acid residues, with a predicted molecular weight of 18,404 and a isoelectric point of 9.93. Three injections of either 10 or 20 microg of the affinity-purified recombinant NspA protein efficiently protected 80% of the mice against a meningococcal deadly challenge comparatively to the 20% observed in the control groups. The fact that the NspA protein can elicit the production of bactericidal and protective antibodies emphasize its potential as a vaccine candidate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9104804      PMCID: PMC2196255          DOI: 10.1084/jem.185.7.1173

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  64 in total

1.  Outer membrane proteins of Neisseria meningitidis: structure and importance in meningococcal disease.

Authors:  C E Frasch; C M Tsai; L F Mocca
Journal:  Clin Invest Med       Date:  1986       Impact factor: 0.825

2.  Classification of Neisseria meningitidis group B into distinct serotypes. 3. Application of a new bactericidal-inhibition technique to distribution of serotypes among cases and carriers.

Authors:  C E Frasch; S S Chapman
Journal:  J Infect Dis       Date:  1973-02       Impact factor: 5.226

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine.

Authors:  A L Reingold; C V Broome; A W Hightower; G W Ajello; G A Bolan; C Adamsbaum; E E Jones; C Phillips; H Tiendrebeogo; A Yada
Journal:  Lancet       Date:  1985-07-20       Impact factor: 79.321

5.  Prevention of meningococcal disease by group C polysaccharide vaccine.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; H Schneider; C Harkins
Journal:  N Engl J Med       Date:  1970-02-19       Impact factor: 91.245

6.  Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

Authors:  E L Anderson; T Bowers; C M Mink; D J Kennedy; R B Belshe; H Harakeh; L Pais; P Holder; G M Carlone
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody.

Authors:  B R Brodeur; Y Larose; P Tsang; J Hamel; F Ashton; A Ryan
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

8.  Human immunity to the meningococcus. II. Development of natural immunity.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

9.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  41 in total

1.  Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci.

Authors:  Yanwen Li; Yao-hui Sun; Cathy Ison; Myron M Levine; Christoph M Tang
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

2.  The phasevarion: a genetic system controlling coordinated, random switching of expression of multiple genes.

Authors:  Yogitha N Srikhanta; Tina L Maguire; Katryn J Stacey; Sean M Grimmond; Michael P Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-31       Impact factor: 11.205

3.  Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant.

Authors:  Jeannette N Williams; Paul J Skipp; Holly E Humphries; Myron Christodoulides; C David O'Connor; John E Heckels
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

4.  Expression of the iron-activated nspA and secY genes in Neisseria meningitidis group B by Fur-dependent and -independent mechanisms.

Authors:  Yazdani B Shaik; Susan Grogan; Michael Davey; Shite Sebastian; Sulip Goswami; Borys Szmigielski; Caroline A Genco
Journal:  J Bacteriol       Date:  2006-11-03       Impact factor: 3.490

5.  Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine.

Authors:  Peter T Beernink; Jo Anne Welsch; Lee H Harrison; Arunas Leipus; Sheldon L Kaplan; Dan M Granoff
Journal:  J Infect Dis       Date:  2007-04-05       Impact factor: 5.226

6.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

Review 7.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

8.  Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein.

Authors:  N Cadieux; M Plante; C R Rioux; J Hamel; B R Brodeur; D Martin
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

9.  Identification of group B streptococcal Sip protein, which elicits cross-protective immunity.

Authors:  B R Brodeur; M Boyer; I Charlebois; J Hamel; F Couture; C R Rioux; D Martin
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 10.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.